Skip to main content
main-content

01.12.2016 | Research article | Ausgabe 1/2016 Open Access

BMC Musculoskeletal Disorders 1/2016

Prevalence of biologics monotherapy in a cohort of patients with Rheumatoid Arthritis in daily clinical practice

Zeitschrift:
BMC Musculoskeletal Disorders > Ausgabe 1/2016
Autoren:
Erika Catay, Maximiliano Bravo, Javier Rosa, Enrique R. Soriano
Wichtige Hinweise

Competing interests

E.R. S. has received grants, participated in advisory boards, or given conferences for: Abbvie, Pfizer, Bristol Myers Squibb, UCB, Roche, Novartis, and Janssen
J.R. has participated in advisory boards or given conferences for: Abbvie, Pfizer and Bristol Myers Squibb.
Other authors declare not having any competing interests.

Authors’ contributions

ERS was involved in the conception and design of the study, statistical analysis, and interpretation of data, and revising the manuscript critically for important intellectual content. JR was involved in the conception and design of the study and revising the manuscript critically for important intellectual content. EC and MB were involved in data acquisition and drafting the manuscript. All authors gave final approval of the version to be published.

Abstract

Background

Real-life registry data reveal approximately one-third of patients taking biologic agents use them as monotherapy, in spite that combination therapy with Disease Modifying Drugs is more efficacious than monotherapy. The aim of our study was to assess the prevalence of biologics monotherapy in a cohort of patients with RA followed at a single center, and to analyze the reasons for monotherapy, including patients with prescriptions that do not take the medication.

Methods

All patients with Rheumatoid Arthritis, with biologic therapy followed at our Rheumatology Unit were included. Prevalence and reasons for biologics monotherapy was calculated in general, for each biologic course and for each biologic. Prescription data was obtained from the Electronic Medical Record, and drugs acquisition was obtained from the Hospital Administrative database. Drug survival was also calculated and compared between monotherapy and combination therapy.

Results

Seventy nine patients with 115 courses of biologic treatments were included. In 40 (35 %, 95 % CI: 26–44 %) of all biologics courses, biologics were initiated as monotherapy. In 27 courses (23 %, 95 % CI: 16–32 %) biologic monotherapy was prescribed by the treating rheumatologists, and in the other 13 (11 %, 95 % CI: 6–18 %) it was initiated as such by decision of the patient regardless of the physician indication. Reasons for prescription of biologic monotherapy by the treating rheumatologists were adverse events with previous DMARDs in 55.5 %, and was not specified in the remaining courses. Only 25 % of biologics’ courses were monotherapy from the beginning to the end of the biologic therapy. The overall survival on biologics was 45 % (95 % CI: 35–55 %) at 3 years. There were no statistically differences in biologics survival by modality (monotherapy vs combination) (p = 0.543), course (p = 0.4454), or by biologic drug (p = 0.9612).

Conclusions

Almost 1/3 of patients on biologics use them as monotherapy. This is due to physician’s preferences in 60 % of the cases, and to patients not compliance with the indication in around 40 % of the cases. Better communications is needed to assure that physicians and patients agree on the prescribed and used medication.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2016

BMC Musculoskeletal Disorders 1/2016 Zur Ausgabe

Arthropedia

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, DICOM-Daten, Videos und Abbildungen. » Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Orthopädie und Unfallchirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise